Login to Your Account



Pharmion Gets 'Full Approval' For Vidaza In MDS Subtypes

By Kim Coghill


Friday, May 21, 2004
Pharmion Corp.'s value soared 47.8 percent Thursday after the FDA issued full approval of Vidaza, the firm's orphan drug for myelodysplastic syndromes (MDS). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription